Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025980 | 0.94 | HSD11B1 (0.40) | HSD11B1HTR2ADRD2DRD3HTT | |
| SCHEMBL14092992 | 0.87 | HSD11B1 (0.43) | HSD11B1CYP1A2CYP2D6 | |
| SCHEMBL12560562 | 0.87 | HSD11B1 (0.43) | HSD11B1CYP1A2CYP2D6 | |
| SCHEMBL6784201 | 0.84 | DRD2 (0.47) | DRD2DRD3 | |
| SCHEMBL23132919 | 0.84 | HSD11B1 (0.36) | HSD11B1HTR2ADRD2DRD3L3MBTL1 | |
| SCHEMBL3477269 | 0.84 | HSD11B1 (0.36) | HSD11B1HTR2ADRD2DRD3L3MBTL1 | |
| SCHEMBL23108745 | 0.84 | HSD11B1 (0.36) | HSD11B1HTR2ADRD2DRD3L3MBTL1 | |
| SCHEMBL23995928 | 0.83 | HSD11B1 (0.49) | HSD11B1HTTL3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL22142323 | 0.83 | HSD11B1 (0.49) | HSD11B1HTTL3MBTL1CYP1A2CYP2D6 | |
| SCHEMBL18199673 | 0.83 | HSD11B1 (0.49) | HSD11B1HTTL3MBTL1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2023-05-11 | — | — | US | disclosed |
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NodThera Limited (GB) | 2023-05-11 | — | — | US | disclosed |
| US-11518757-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NodThera Limited (GB) | 2022-12-06 | — | — | US | disclosed |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390896-B2 | Cyclic malonamides as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390802-B2 | Substituted lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA CORPORATION (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-05-01 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-7304056-B2 | Succinoylamino lactams as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7276496-B2 | Cyclic malonamides as inhibitors of Aβ protein protection | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221087-A1 | Substituted lactams as inhibitors of abeta protein production | BACE1, APP, APH1A | HSD11B1 770/4885HTR2A 2753/4885DRD2 4124/4885 |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | HSD11B1 4448/4885HTR2A 2243/4885DRD2 4644/4885 |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | APP, BACE1, APH1A | HSD11B1 244/4885HTR2A 515/4885DRD2 3969/4885 |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | HSD11B1 3943/4885HTR2A 4712/4885DRD2 1571/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | HSD11B1 3051/4885HTR2A 3760/4885DRD2 4865/4885 |
| US-20230145050-A1 | SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS | NLRP3, NOD1, IL1B | HSD11B1 2423/4885HTR2A 4734/4885DRD2 4859/4885 |
| US-20220119382-A1 | RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RET, SLC10A2, REL | HSD11B1 550/4885HTR2A 2089/4885DRD2 2857/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | HSD11B1 3051/4885HTR2A 3760/4885DRD2 4865/4885 |
| US-20080275024-A1 | CYCLIC MALONAMIDES AS INHIBITORS OF ASS PROTEIN PRODUCTION | APP, BACE1, APH1A | HSD11B1 850/4885HTR2A 4279/4885DRD2 4569/4885 |
| US-20220177508-A1 | C10-Cyclic Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL12, RPL13A | HSD11B1 174/4885HTR2A 3469/4885DRD2 3281/4885 |
| US-20080103128-A1 | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF ABETTA PROTEIN PRODUCTION | APH1A, APH1B, APP | HSD11B1 1059/4885HTR2A 2304/4885DRD2 4375/4885 |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | HSD11B1 3695/4885HTR2A 4831/4885DRD2 4874/4885 |
| US-11518757-B2 | Sulphonyl urea derivatives as NLRP3 inflammasome modulators | NLRP3, NOD1, IL1B | HSD11B1 2423/4885HTR2A 4734/4885DRD2 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.